CLDN18.2 tumor status was assessed in 2,104 patients, of whom 808 (38.4%) had tumors that met the cutoff for CLDN18.2 positivity (≥75% of tumor cells with moderate-to-strong CLDN18 membranous staining as determined by central immunohistochemistry using the investigational VENTANA CLDN18 (43-14A) RxDx assay). The gene discussed is CLDN18; the disease is neoplasm.